Announced details
Regenerative medicine and medical clinics
A business relationship in which the Company’s consolidated subsidiary, ADR Therapeutics, supplies and delivers products to the counterparty
General incorporated association based in Fukuoka Prefecture and operating 12 medical clinics nationwide
Fukuoka Prefecture (the counterparty’s base)
Aggregate sales amount equivalent to 20% of the Company’s sales in the immediately preceding fiscal year, the fiscal year ended March 2026
The impact on consolidated results for the fiscal year ending March 2027 is currently under review
The company does not address Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Products related to the high-concentration exosome component-containing liquid “NeoCella (ネオセラ)” |
| Counterparty | General incorporated association (based in Fukuoka Prefecture, operating 12 medical clinics nationwide; name undisclosed) |
| Counterparty overview | General incorporated association based in Fukuoka Prefecture and operating 12 medical clinics nationwide |
| Relationship with the Company | A business relationship in which the Company’s consolidated subsidiary, ADR Therapeutics, supplies and delivers products to the counterparty |
| Contract Value | Aggregate sales amount equivalent to 20% of the Company’s sales in the immediately preceding fiscal year, the fiscal year ended March 2026 |
| Launch date | 16 November 2026 (scheduled delivery date) |
| Applicable area | Regenerative medicine and medical clinics |
| Location | Fukuoka Prefecture (the counterparty’s base) |
| Location scale | 12 medical clinics nationwide |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is currently under review |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The disclosure states that ADR Therapeutics has been developing the organizational structure for NeoCella’s research and development and sales operations, and that the products will be supplied and delivered to a general incorporated association operating multiple medical clinics.